================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 2, 2001 (November 2, 2001)
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-26727 68-0397820
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
371 Bel Marin Keys Boulevard, 94949
Suite 210 (Zip Code)
Novato, California
(Address of principal executive offices)
(415) 884-6700
------------------------------------------------
(Registrant's telephone number, including area code)
================================================================================
Item 5. Other Events
On November 2, 2001, we announced the results of our Phase III trial of
Aldurazyme for the treatment of MPS I in a press release dated November 2, 2001.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
Item 7. Financial Statements and Exhibits
EXHIBIT NO. DESCRIPTION OF DOCUMENT
------------ ------------------------------------------------------------------
99.1 Press Release Dated November 2, 2001 Related to the Announcement
of the Results of the Phase III Trial of Aldurazyme for the
Treatment of MPS I.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BioMarin Pharmaceutical Inc.
By: /s/ Raymond W. Anderson
---------------------------------
Raymond W. Anderson
Chief Operating Officer, Chief Financial
Officer, Secretary and Vice President Finance
and Administration
Date: November 2, 2001
Exhibit Index
EXHIBIT NO. DESCRIPTION OF DOCUMENT
------------ ------------------------------------------------------------------
99.1 Press Release Dated November 2, 2001 Related to the Announcement
of the Results of the Phase III Trial of Aldurazyme for the
Treatment of MPS I.